



RECEIVED

PATENT

MAR 17 1988

GROUP 12U

3
880
3-18-88

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

127

BRANCA ET AL.

Group: 125 / 21

Serial No. 07/119,114, filed November 10, 1987

K. BRISCOE

For: TETRAHYDRONAPHTHALENE DERIVATIVES


INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
February 29, 1988

Honorable Commissioner of Patents & Trademarks
Washington, D.C. 20231

Sir:

This statement is submitted pursuant to and in compliance with the provisions of 1.56, 1.97 and 1.98 of Title 37 of the Federal Regulations as amended. The invention relates to compounds of the formula



I


wherein R is lower-alkyl, R¹ is halogen, R² is C₁-C₁₂-alkyl, R³ is hydroxy, lower-alkoxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyloxy, lower-alkylaminocarbonyloxy, arylaminocarbonyloxy or aryl-lower-alkylaminocarbonyloxy, X is C₁-C₁₈-alkylene, C₁-C₁₈-alkylene which is interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene, A is di- or tri-substituted 2-imidazolyl attached via an ethylene group or a substituted or unsubstituted heterocycle selected from the group consisting of benzimidazolyl, benzimidazolonyl, imidazo[4,5-c]pyridinyl, imidazo[4,5-c]-pyridinonyl, benzthiazolyl, benzodiazepine-2,5-dion-1-yl and pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dion-10-yl and n is the number 0 or 1, in the form of racemates and optical antipodes, as well as N-oxides and pharmaceutically usable acid addition salts thereof.

These compounds are calcium antagonists and have anti-arrhythmic activity and accordingly can be used as medicines especially for the control or prevention of angina pectoris, ischemia, arrhythmias, high blood pressure and cardiac insufficiency.

In connection with the foregoing invention, the applicants wish to bring the following publication to the attention of the Patent and Trademark Office:

(1) U.S. Patent No. 4,680,310 - This patent is listed in attached PTO Form-1449 and a copy is enclosed for convenience.

Publication (1) - Discloses compounds of the formula



wherein R is hydrogen or lower-alkyl, R¹, R², R³ and R⁴ each independently is hydrogen, halogen or lower-alkoxy or two adjacent residues together are methylenedioxy or ethylenedioxy, R⁵, R⁶, R⁷, R⁸ and R⁹ each independently is hydrogen, halogen, C₁-C₁₀-alkoxy, lower alkylthio, lower-alkoxy-lower-alkoxy or ω,ω,ω -trifluoro-lower-alkoxy or two adjacent residues together are methylenedioxy or ethylenedioxy, Y is hydroxy, lower-alkylcarbonyloxy, lower-alkoxy-lower-alkylcarbonyloxy, lower-alkoxy-carbonyloxy, lower-alkoxy-lower-alkoxycarbonyloxy, lower-alkylthio-lower-alkylcarbonyloxy or optionally substituted benzylcarbonyloxy, m is the number 1 or 2 and n is the number 1, 2 or 3, in the form of racemates and optical antipodes, as well as pharmaceutically usable acid addition salts thereof.

These compounds differ from the claimed compounds in having a phenyl-C₂-C₄-alkyl side chain rather than a heterocyclic ring bound to the remainder of the molecule via a C₁-C₁₈-alkylene group, which can be interrupted by 1,4-phenylene or interrupted or lengthened by 1,4-cyclohexylene.

The Examiner is respectfully requested to consider the above publication in connection with the examination of the captioned application. The applicants respectfully submit that while the publication may bear upon the state of the art, it does not suggest or render obvious the claimed invention.

The Examiner is hereby authorized to call the undersigned attorney of record "collect" on any matter connected with this application. The telephone number is Area Code (201) 235-5171. In the absence of the undersigned attorney of record, the call will be accepted by another attorney empowered in this application.

Respectfully submitted,

Matthew Boxer
Attorney for Applicants

Matthew M. Boxer
(Reg. No. 28495)
340 Kingsland Street
Nutley, New Jersey 07110

MB:jd
4053P